Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

Post by RetailRubeon Jul 29, 2014 2:36pm
317 Views
Post# 22790975

Orphan Drug Status vs Fast Track Designation

Orphan Drug Status vs Fast Track DesignationToday, as you know, Bioniche announced they submitted their application to the FDA for Orphan Drug Status for MCNA.  A decision by the FDA is expected within 90 days.  That means end-of-October this year.  So we will know by the time we get together in Belleville for the AGM in early November.

What does Orphan Drug Status mean?  Here is a summary of what I read in Wikipedia:

Several decades ago, the US governement increased the amount of testing required before a drug could be approved.  This was to avoid a repeat of the Thalydomide scandal.  However, the increased clinical trial cost meant it was no longer economic for pharma companies to develop treatments for diseases with relatively rare incidence (lower annual revenue).  These rare diseases became "orphaned" as pharma companies abandoned their trials for them.  Thefore, the US created the Orphan Drug category which received financial incentives to offset the poor business case.  These sweeteners included longer patent protection and lower FDA application fees.

But Orphan Drug Status does not mean faster approval, as far as I can determine.

Faster approval comes from "FDA Fast Track Designation".

From a press release dated May 04, 2006:  "Bioniche today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company's proprietary Mycobacterial Cell Wall-DNA Complex (MCC - trademarked Urocidin) for the treatment of non-muscle invasive bladder cancer in patients who are refractory (unresponsive) to Bacillus Calmette-Guerin (BCG), the current standard therapy."  "This FDA Fast Track designation means that, when data from the Phase III program becomes available, the Company could expect an expedited review of its Biologics Licensing Application for Urocidin."

I do not know if there is an expiry date on Fast Track Status.  I also do not know if Endo used up that status during their discussions of Phase 3a results with the FDA, which led to the ill-fated Phase 3b trial, subsequently abandoned.  However, since it refers to faster review of the BLA (which was never submitted) then just maybe this Fast Track Status is still alive.

If we have both of these designations, then it doesn't get much better than this.  Right?


<< Previous
Bullboard Posts
Next >>